ABN AMRO Bank N.V. Boosts Stock Position in Medtronic PLC $MDT

Key Points

• ABN AMRO Bank N.V. increased its Medtronic stake by 42.3% in the fourth quarter, buying 24,473 additional shares and lifting its position to 82,306 shares worth about $7.9 million.
• Medtronic recently posted better-than-expected quarterly results, with EPS of $1.36 and revenue of $9.02 billion, both topping analyst estimates. The company also raised its FY 2026 EPS guidance to $5.620-$5.660.
• The stock has come under pressure, trading near its 52-week low around $76, even as analysts remain broadly constructive with a consensus rating of “Moderate Buy” and an average target price of $107.80.

ABN AMRO Bank N.V. boosted its holdings in shares of Medtronic PLC (NYSE:MDT - Free Report) by 42.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 82,306 shares of the medical technology company's stock after purchasing an additional 24,473 shares during the quarter. ABN AMRO Bank N.V.'s holdings in Medtronic were worth $7,896,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Brighton Jones LLC increased its holdings in shares of Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company's stock valued at $3,194,000 after acquiring an additional 37,265 shares during the last quarter. Sivia Capital Partners LLC increased its holdings in shares of Medtronic by 9.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company's stock valued at $380,000 after acquiring an additional 381 shares during the last quarter. Jump Financial LLC bought a new stake in shares of Medtronic in the 2nd quarter valued at approximately $299,000. Main Street Financial Solutions LLC increased its holdings in shares of Medtronic by 28.9% in the 2nd quarter. Main Street Financial Solutions LLC now owns 14,356 shares of the medical technology company's stock valued at $1,251,000 after acquiring an additional 3,218 shares during the last quarter. Finally, HUB Investment Partners LLC increased its holdings in shares of Medtronic by 21.3% in the 2nd quarter. HUB Investment Partners LLC now owns 19,226 shares of the medical technology company's stock valued at $1,676,000 after acquiring an additional 3,376 shares during the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Trading Down 0.2%

Shares of Medtronic stock opened at $76.03 on Monday. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The firm has a market cap of $97.62 billion, a price-to-earnings ratio of 21.18, a price-to-earnings-growth ratio of 1.81 and a beta of 0.62. The business has a fifty day simple moving average of $87.26 and a 200-day simple moving average of $94.43. Medtronic PLC has a fifty-two week low of $75.91 and a fifty-two week high of $106.33.

Medtronic (NYSE:MDT - Get Free Report) last announced its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. The business had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company's revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities analysts forecast that Medtronic PLC will post 5.57 EPS for the current fiscal year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 17th. Stockholders of record on Friday, March 27th were issued a $0.71 dividend. The ex-dividend date was Friday, March 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.7%. Medtronic's dividend payout ratio is 79.11%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Daiwa Securities Group lowered their price target on Medtronic from $117.00 to $115.00 and set a "buy" rating for the company in a report on Friday, February 27th. UBS Group lowered their price target on Medtronic from $104.00 to $90.00 and set a "neutral" rating for the company in a report on Wednesday, April 22nd. Evercore set a $106.00 price target on Medtronic and gave the company an "outperform" rating in a report on Thursday, April 9th. Piper Sandler lowered their price target on Medtronic from $105.00 to $91.00 and set a "neutral" rating for the company in a report on Wednesday, April 1st. Finally, Jefferies Financial Group restated a "hold" rating and set a $95.00 price objective on shares of Medtronic in a research report on Thursday, April 23rd. Fifteen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat, Medtronic currently has an average rating of "Moderate Buy" and an average target price of $107.80.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic received the CE Mark for its Stealth AXiS system, adding to the earlier FDA approval and expanding the next-generation planning, navigation, and robotics platform into Europe. That strengthens the company’s surgical robotics and imaging portfolio and could support future procedure growth. Following FDA Approval, Medtronic (MDT) Receives CE Mark For Stealth AXiS System
• Positive Sentiment: Medtronic expanded its neuromodulation business by launching Adaptive Deep Brain Stimulation for Parkinson’s disease in India, which broadens its reach in a large and growing market and highlights continued innovation in its neurological therapies segment. Medtronic Expands Neuromodulation Reach With Adaptive DBS Launch In India
• Neutral Sentiment: Several articles focused on whether MDT looks attractive after recent share-price weakness and whether Wall Street’s bullish analyst views make the stock worth buying. These pieces can keep attention on the name, but they did not add new fundamental data. Is Medtronic (MDT) Offering Value After Recent Share Price Weakness? Is It Worth Investing in Medtronic (MDT) Based on Wall Street's Bullish Views?
• Neutral Sentiment: Third-party “best stocks” and retiree-income articles also mentioned Medtronic, which may provide some investor visibility, but these are largely promotional and not direct company-specific catalysts. 3 Healthcare Stocks Every Retiree Should Consider Better Than Intuitive Surgical? 1 Under-the-Radar Healthcare Stock to Buy and Hold Forever

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the company's stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 0.26% of the stock is currently owned by company insiders.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.